Adma Biologics Stock Last Dividend Paid
| ADMA Stock | USD 19.13 0.69 3.74% |
ADMA Biologics fundamentals help investors to digest information that contributes to ADMA Biologics' financial success or failures. It also enables traders to predict the movement of ADMA Stock. The fundamental analysis module provides a way to measure ADMA Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ADMA Biologics stock.
ADMA |
ADMA Biologics Company Last Dividend Paid Analysis
ADMA Biologics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, ADMA Biologics has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
ADMA Fundamentals
| Return On Equity | 0.36 | ||||
| Return On Asset | 0.2 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 4.38 B | ||||
| Shares Outstanding | 236.39 M | ||||
| Shares Owned By Insiders | 2.51 % | ||||
| Shares Owned By Institutions | 91.78 % | ||||
| Number Of Shares Shorted | 12.18 M | ||||
| Price To Earning | (1.55) X | ||||
| Price To Book | 18.80 X | ||||
| Price To Sales | 11.39 X | ||||
| Revenue | 258.21 M | ||||
| Gross Profit | 35.27 M | ||||
| EBITDA | 5.12 M | ||||
| Net Income | (28.24 M) | ||||
| Cash And Equivalents | 52.42 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 141.42 M | ||||
| Debt To Equity | 1.32 % | ||||
| Current Ratio | 7.94 X | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | 8.8 M | ||||
| Short Ratio | 4.55 X | ||||
| Earnings Per Share | 0.27 X | ||||
| Target Price | 24.62 | ||||
| Number Of Employees | 624 | ||||
| Beta | 0.65 | ||||
| Market Capitalization | 4.36 B | ||||
| Total Asset | 329.18 M | ||||
| Retained Earnings | (506.26 M) | ||||
| Working Capital | 207.21 M | ||||
| Current Asset | 21.29 M | ||||
| Current Liabilities | 4.22 M | ||||
| Net Asset | 329.18 M |
About ADMA Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ADMA Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out ADMA Biologics Piotroski F Score and ADMA Biologics Altman Z Score analysis. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.